FOXP3 and cancer: Our data show that Tregs recognized by NEO-201 express a high percentage of Foxp3+/CD15s+ cells (average 66.14%), suggesting that NEO-201 can recognize highly suppressive Tregs in the peripheral blood of cancer patients (Supplementary Fig. 3).